secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016326
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine shareholders approve 1-for-17 reverse stock split effective May 11, 2023
--------------------------------------------------------------------------------

- Reverse split ratio set at 1-for-17, effective 5:00 p.m. ET May 11, 2023; shares trade split-adjusted May 12.
- Post-split shares outstanding approximately 5.2 million; no fractional shares issued (rounded up).
- All stock options and warrants proportionally adjusted; new CUSIP 53630X203.
- Shareholders elected six directors, ratified Tanner LLC as auditor, and approved advisory say-on-pay.
- Series B Preferred Stock votes counted on reverse split and adjournment proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315223016326/0001493152-23-016326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315223016326/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer